The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-naive patients with benign prostatic hyperplasia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Benign prostatic hyperplasia (BPH) is one of the most common diseases in men over 50 years. The prevalence of the BPH increases with age, and pathologic features of BPH are found in about 90% of men over 80 years. Aim. The aim of the study was to study the efficacy and safety of Afalaza for the treatment of lower urinary tract symptoms (LUTS) in treatment-naive patients with BPH. Materials and methods. A multicenter study of using Afalaza for the treatment of LUTS in treatment-naive patients with BPH was carried out in 9 urological centers in Moscow. A total of 80 treatment-naive patients with BPH were enrolled. The improvement in the total score of IPSS, IIEF-5 and QoL after 30 weeks of therapy was evaluated as well as changes in prostate volume and maximum urinary flow rate (Qmax). Results. After 30 weeks of therapy, there was a significant decrease in the total IPSS score. A decrease in the total IPSS score by 5.5 points (+37.9%) from 14.5+4.0 at the baseline to 9.0+4.1 at the visit 9 was seen. The QoL decreased by 1.8 (-38.3%) points from 4.7+1.0 at the baseline. The Qmax also changed from 12.7+4.6 to 16.4+5.7 (+28.3%) after 30 weeks of therapy. At the visit 9, the total IIEF5 score increased by 3.4+4.4 (+19.9%) from 17.1+4.3 at the baseline. In addition, prostate volume decreased from 42.7+11.1 at baseline to 41.0+9.8 cc post-treatment (-5.15%). A reduction of post-void residual urine volume from 26.0+25.3 at baseline to 17.7+24.2 (-31.9%) post-treatment was also shown. Conclusion. The results of a multicenter study demonstrate the efficacy of Afalaza for treatment of treatment-naive patients with LUTS/BPH. Afalaza reduces prostate volume and improves an erectile function.

Full Text

Restricted Access

About the authors

Yu. A Kupriyanov

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia; Municipal clinical hospital named after S.I. Spasokukotskiy

Email: Dr.kupriyanov@gmail.com
Ph.D., assistant at the Department of Urology; urologist

P. I. Rasner

A.I. Evdokimov Moscow State University of Medicine and Dentistry; Municipal clinical hospital named after S.I. Spasokukotskiy of the Moscow

Email: dr.rasner@gmail.com
MD, professor, MD, professor at the Department of Urology; Head of the Department of Urology №4 Healthcare Department

I. M Rokhlikov

GBUZ CP №68 of Moscow Health Department

Email: rohim@urol-androl.ru
Ph.D., urologist and andrologist, chief specialist of Central Administrative Okrug

A. A Akrikidi

GBUZ CP №29 of Moscow Health Department

Email: akritas@list.ru
urologist and andrologist, chief specialist of South-East Administrative Okrug

V. V Soloviev

GBUZ CP №170 of Moscow Health Department

Email: 1699380@gmail.com
deputy director for clinical work, urologist

A. A Markov

GBUZ CP №107 of Moscow Health Department

Email: alek-markov@ya.ru
urologist, Okrug specialist

E. V Nozdrin

GBUZ CP №201 of Moscow Health Department

Email: std83@mail.ru
Head of the Department of Urology, urologist

L. A Logvinov

GBUZ CP №69 of Moscow Health Department

Email: leolog@rambler.ru
urologist, chief specialist of East Administrative Okrug

R. P Vasilevskiy

GBUZ CP №134 of Moscow Health Department

Email: urolog-rv@yandex.ru
urologist, chief specialist of South-West Administrative Okrug

K. S Skrupskiy

Municipal clinical hospital named after S.I. Spasokukotskiy

Email: 89_sks@mail.ru
urologist at the Department of Oncourology

D. Yu Pushkar

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: pushkardm@mail.ru
MD, professor, corresponding member of RAS, Chief urologist of the Ministry of Health of Russia and Moscow, General scientific secretary of Russian Society of Urology, Head of the Department of Urology

M. A Putilovskiy

NPF «Materia Medica Holding» LTD

Email: putilovskiyma@materiamedica.ru
Ph.D., Director of Clinical and Medical Department

O. I Epstein

FGBUN Research Institute of General Pathology and Pathophysiology

Email: epstein@mail.ru
MD, professor, corresponding member of RAS, Head of the Laboratory of physiologically active substances

References

  1. Раснер П.И., Газимиев М.А., Гаджиева З.К., Касян Г.Р. Расстройства мочеиспускания у мужчин. Методические рекомендации № 6. М.: ООО «ИД «АБВ-пресс». 2017.С. 35
  2. Egan K.B. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol. Clin. North. Am. 2016;43:289-297.
  3. Hutchison A., Farmer R., Verhamme K., Berges R., Navarrete R. V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. European urology. 2007;51(1):207-216.
  4. Djavan B., Chapple C., Milani S., Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64:1081-1088.
  5. Emberton M., Cornel E.B., Bassi P.F., Fourcade R.O., Gomez J.M.F., Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int. J. Clin. Pract. 2008;62:1076-1086.
  6. Oelke M., Bachmann A., Descazeaud A. European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 2013;64:118-140.
  7. Kolontarev K., Govorov A., Kasyan G., Priymak D., Pushkar D. Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. Cent. European. J. Urol. 2016;69:398-403.
  8. Pushkar D., Tarasov S., Putilovskiy M. Mild-to-moderate Benign Prostatic Hyperplasia (BPH) symptoms: Filling the gap. 16-th Meeting of the Association of Academic European Urologists (AAEU). Dresden, Germany. December 14-16; 2017. Р. 51-52.
  9. Fusco F., Palmieri A., Ficarra Кш-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. Eur Urol. 2016;69: 1091-1101.
  10. Epstein O. The spatial homeostasis hypothesis. Symmetry. 2018;10(4):103. doi: 10.3390/sym10040103.
  11. Гудков А.В. Опыт длительного применения афалы при доброкачественной гиперплазии предстательной железы. Бюл. экспер. биол. 2009;148(8):57-60
  12. Эпштейн О.И. Релиз-активность (современный взгляд на гомеопатию и негомеопатию). М.: Издательство РАМН. 2017. 48 с.
  13. Pushkar D., Vinarov A., Spivak L., Kolontarev K.,PutilovskiyM,Andrianova E., Epstein О. Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, doubleblind, placebo-controlled, randomized clinical trial. Central Eur J. Urol. 2018;71:427-435. doi: 10.5173/ceju.2018.1803.
  14. Mkrtumyan A., Romantsova T., Vorobiev S., Volkova A., Vorokhobina N., Tarasov S., Putilovskiy M., Andrianova E., Epstein O. Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Diabetes Res Clin Pract. 2018;142:1-9.
  15. Rafalsky V., Averyanov A., Bart B., Minina E., Putilovskiy M., Andrianova E., Epstein O. Efficacy and safety of Ergoferon versus oseltamivir in Adult outpatients with seasonal influenza virus infection: a multicenter open-Label randomized trial. Int J. Infect Dis. 2016;51:47-55.
  16. Bailbe D., Philippe E., Gorbunov E., Tarasov S., Epstein O., Portha B. The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone. J. Diab Res. 2013;13(1):763125 p. doi: 10.1155/2013/763125.
  17. Castagne V., Lemaire M., Kheyfets I., Dugina J.L., Sergeeva S.A., Epstein O.I. Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat. J. Pharm Pharmacol. 2008;60(3):309-316.
  18. Chu X., Zhavbert E.S., Dugina Y.L., Kheifets I.A., Sergeeva S.A., Epstein O.I., Agmo A. Sildenafil and a compound stimulating endothelial NO synthase modify sexual incentive motivation and copulatory behavior in male Wistar and Fisher 344 rats. International Society for Sexual Medicine. 2008;5:2085-2099.
  19. Jacobsen S.J., Jacobson D.J., Girman C.J. etal. Natural History of Prostatism: Risk Factors for Acute Urinary Retention. J. Urol. 1996;155:595-600.
  20. Roehrborn C.G., McConnell J., Bonilla J. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J. Urol. 2000;163:13-20.
  21. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl J. Med. 1998;338:557-563.
  22. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl J. Med. 2003;349: 2387-2398.
  23. Forstermann U., Sessa W.C. Nitric oxide synthases: regulation and function. Eur. Heart. J. 2012;33:829-837.
  24. Неймарк А.И., Алиев Р.Т., Музалевская Н.И. и др. Использование импазы в лечении эректильной дисфункции у пациентов с гипертонической болезнью и ИБС. Bulletin of Experimental Biology and Medicine. 2009; 148: 328

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media